| Autor: |
Waxman JH, Wass JA, Hendry WF, Whitfield HN, Bary P, Besser GM, Malpas JS, Oliver RT |
| Jazyk: |
angličtina |
| Zdroj: |
British journal of urology [Br J Urol] 1983 Dec; Vol. 55 (6), pp. 737-42. |
| DOI: |
10.1111/j.1464-410x.1983.tb03416.x |
| Abstrakt: |
Twenty-two consecutive patients with newly diagnosed symptomatic, locally advanced or metastatic prostate cancer were treated with intranasal buserelin, a long-acting analogue of gonadotrophin releasing hormone, in divided dosages of between 600 and 1000 micrograms daily. Suppression of testosterone occurred in 1 of 5 patients treated with 600 micrograms daily and in all 17 patients receiving 1000 micrograms daily. Two of 5 patients treated with the 600 micrograms regimen and 16 of 17 patients receiving the 1000 micrograms regimen showed subjective and objective evidence of disease regression. Follow-up was from 1 to 16 months (mean 7.1 months); 6 patients have relapsed during this period. Buserelin offers an effective alternative medical treatment of carcinoma of the prostate and, apart from impotence, does not have the side effects of oestrogens. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text